TG Therapeutics Highlights Presentation Of Interim Data From UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy In Patients With Marginal Zone Lymphoma At 2019 AACR Annual Meeting
Benzinga Newsdesk